External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Specialty Chemicals &amp; CDMO Transition Improving Earnings Quality: Jubilant Ingrevia Limited continues to successfully transition from a cyclical commodity-led portfolio toward high-margin Specialty Chemicals, CDMO and Nutrition businesses.</li><li>Specialty Chemicals now contribute the majority of consolidated EBITDA with sustainable margins of ~25%+, supported by strong growth in Pyridine derivatives, Fine Chemicals, and CDMO opportunities.</li><li>The commissioning of the Bharuch Agro CDMO facility and expanding pharma CDMO pipeline provide strong medium-term earnings visibility.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Specialty Chemicals &amp; CDMO Transition Improving Earnings Quality: Jubilant Ingrevia Limited continues to successfully transition from a cyclical commodity-led portfolio toward high-margin Specialty Chemicals, CDMO and Nutrition businesses.Specialty Chemicals now contribute the majority of consolidated EBITDA with sustainable margins of ~25%+, supported by strong growth in Pyridine derivatives, Fine Chemicals, and CDMO opportunities.The commissioning of the Bharuch Agro CDMO facility and expanding pharma CDMO pipeline provide strong medium-term earnings visibility.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jubilant Ingrevia Ltd - Specialty & CDMO Momentum Accelerates